Head to Head Survey: Matinas BioPharma Holdings (MTNB) and Exact Sciences Corporation (EXAS)
Matinas BioPharma Holdings (NASDAQ: MTNB) and Exact Sciences Corporation (NASDAQ:EXAS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.
This is a breakdown of recent ratings and target prices for Matinas BioPharma Holdings and Exact Sciences Corporation, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Matinas BioPharma Holdings||0||0||3||0||3.00|
|Exact Sciences Corporation||0||3||10||0||2.77|
Matinas BioPharma Holdings currently has a consensus price target of $7.67, suggesting a potential upside of 513.33%. Exact Sciences Corporation has a consensus price target of $41.31, suggesting a potential downside of 3.37%. Given Matinas BioPharma Holdings’ stronger consensus rating and higher probable upside, analysts plainly believe Matinas BioPharma Holdings is more favorable than Exact Sciences Corporation.
Institutional & Insider Ownership
85.2% of Exact Sciences Corporation shares are held by institutional investors. 4.0% of Exact Sciences Corporation shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares Matinas BioPharma Holdings and Exact Sciences Corporation’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Matinas BioPharma Holdings||-8,834.65%||-143.22%||-79.91%|
|Exact Sciences Corporation||-83.08%||-36.36%||-32.85%|
Valuation and Earnings
This table compares Matinas BioPharma Holdings and Exact Sciences Corporation’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Matinas BioPharma Holdings||$59,875.00||1,920.08||-$12.81 million||N/A||N/A|
|Exact Sciences Corporation||$169.37 million||30.06||-$129.74 million||($1.29)||-33.14|
Matinas BioPharma Holdings has higher revenue, but lower earnings than Exact Sciences Corporation.
Exact Sciences Corporation beats Matinas BioPharma Holdings on 7 of the 11 factors compared between the two stocks.
Matinas BioPharma Holdings Company Profile
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections. Its cochleate delivery technology platform is designed for the targeted delivery of pharmaceuticals directly to the site of infection or inflammation. Its MAT 2203 is an oral formulation of a spectrum anti-fungal drug called amphotericin B, which uses its cochleate delivery technology. Its MAT2501 is an orally administered, encochleated formulation of the spectrum aminoglycoside antibiotic amikacin, which may be used to treat different types of multidrug-resistant bacteria, including non-tubercular mycobacterial infections (NTM), as well as various multidrug-resistant gram negative and intracellular bacterial infections.
Exact Sciences Corporation Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.
Receive News & Ratings for Matinas BioPharma Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.